Table 2.
Chronic GVHD Characteristics at Initiation of Therapy
| Variable | Frequency (%) | |||
|---|---|---|---|---|
|
|
|
|||
| NIH Consensus 0–3 Scores | NIH 0 | NIH 1 | NIH 2 | NIH 3 |
| Skin | 4 (33%) | 2 (17%) | 5 (42%) | 1 (8%) |
| Mouth | 4 (33%) | 6 (50%) | 2 (17%) | 0 |
| Eye | 4 (33%) | 5 (42%) | 2 (17%) | 1 (8%) |
| Lung | 8 (67%) | 2 (17%) | 2 (17%) | 0 |
| GI | 9 (75%) | 2 (17%) | 1 (8%) | 0 |
| Liver | 7 (58%) | 4 (33%) | 0 | 1 (8%) |
| Genital | 10 (83%) | 2 (17%) | 0 | 0 |
| Joint/fascia | 7 (58%) | 2 (17%) | 2 (17%) | 1 (8%) |
| Overall | 0 | 0 | 7 (58%) | 5 (42%) |
| Chronic GVHD onset type | ||||
| De novo | 3 (25%) | |||
| Interrupted | 7 (58%) | |||
| Progressive | 2 (17%) | |||
| Chronic GVHD subtype | ||||
| Classic | 5 (42%) | |||
| Overlap | 7 (58%) | |||
| HCT-CI (at trial enrollment) [49] | ||||
| <3 | 2 (17%) | |||
| ≥3 | 10 (83%) | |||
| KPS | ||||
| <90 | 4 (33%) | |||
| ≥90 | 8 (67%) | |||
| Platelet count, median (range), k/uL | 164 (92–287) | |||
| Bilirubin, mg/dL | .6 (.2–.9) | |||
| Two-minute walk test, median (range), feet [50] | 480 (140–574) | |||
| Baseline systemic immune suppression | ||||
| Sirolimus | 8 (67%) | |||
| Tacrolimus | 10 (83%) | |||
| Prednisone (range, .14–.5 mg/kg daily dose) | 3 (25%) | |||
| ECP | 1 (8%) | |||
| FAM | 2 (17%) | |||
| Baseline topical immune suppression | ||||
| Beclomethasone (GI) | 1 (8%) | |||
| Budesonide (GI) | 2 (17%) | |||
| Triamcinolone (skin) | 2 (17%) | |||
| Dexamethasone (mouth) | 4 (33%) | |||
| Tacrolimus (skin) | 1 (8%) | |||
GI indicates gastrointestinal; HCT-CI, HCT comorbidity index; KPS, Karnofsky performance status; ECP, extracorporeal photopheresis; FAM, combination therapy with fluticasone, azithromycin, monteleukast.